Fundraising FoxGenome Biologics
1 known investors
Find your way into Genome Biologics
Sign up to see every warm intro you have to Genome Biologics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Genome Biologics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Genome Biologics operates a contract research service using TrueCardium, an iPSC-derived multicellular human cardiac organoid platform, to run cardiotoxicity screening, disease modeling, and drug efficacy studies. It serves pharmaceutical and biotechnology partners seeking human-relevant cardiac safety and translational data beyond conventional 2D assays and animal models.
Investors · 1
In the news
Frequently asked questions
- What does Genome Biologics do?
- Genome Biologics operates a contract research service using TrueCardium, an iPSC-derived multicellular human cardiac organoid platform, to run cardiotoxicity screening, disease modeling, and drug efficacy studies. It serves pharmaceutical and biotechnology partners seeking human-relevant cardiac safety and translational data beyond conventional 2D assays and animal models.
- Who are Genome Biologics's investors?
- Genome Biologics's investors include CARMA FUND.